OMB
COST ESTIMATE
FOR PAY-AS-YOU-GO CALCULATIONS
Report No: 568
Date: 01/25/2002
(Fiscal years; in millions of dollars) | ||||||
2001 | 2002 | 2003 | 2004 | 2005 | 2006 | |
Net costs. . . . . . . . . . . . . . . . . . . . | 0 | 0 | 0 | 0 | 0 | 0 |
(Fiscal years; in millions of dollars) | ||||||
2001 | 2002 | 2003 | 2004 | 2005 | 2006 | |
Net costs. . . . . . . . . . . . . . . . . . . . | 0 | -8 | -5 | -4 | -7 | -15 |
In addition to scoring the provision scored by OMB, CBO scores the effects of the Act on direct spending and receipts from potential changes in drug prices resulting from the extension in exclusivity of marketing rights.
The difference between OMB and CBO estimates of net costs is primarily for provisions related to the extension of market exclusivity. CBO scores the impact of changes in drug prices resulting from the changes in market exclusivity; OMB considers these changes in drug prices to be an indirect effect of the Act and thus not scorable for pay-as-you-go purposes.
(Fiscal years; in millions of dollars) | ||||||
2001 | 2002 | 2003 | 2004 | 2005 | 2006 | |
Outlay effect.............. | 5,503 | 18,465 | 23,825 | 23,533 | 22,822 | 8,218 |
Receipt effect............ | -69,768 | -34,950 | -84,840 | -104,135 | -105,311 | -123,752 |
Net costs.................... | 75,271 | 53,415 | 108,665 | 127,668 | 128,133 | 131,970 |